1. Medtech Insight
  2. >>Device Area
  3. >>Cardiology

ESC Roundup: Questions Raised About Remote Monitoring Benefits And Preventative ICDs; Medtronic Upgrades CRT Algorithms

 
• By Reed Miller

This year's European Society of Cardiology Congress in Rome featured presentations of data from several major clinical trials that may cause cardiologists to rethink some of their established device therapies, including ICDs for the primary prevention of sudden cardiac death and remote monitoring of implantable devices in heart-failure patients.

Heart
• Source: Shutterstock

Remote monitoring of cardiac resynchronization defibrillators (CRT-D) did not reduce mortality of heart failure patients beyond the benefits of regular office-based care in the MORE CARE study. However, the trial results also indicate that remote monitoring can reduce the overall costs of treating these patients without compromising patient safety by reducing the number of in-office visits.

Giuseppe Boriani of the University of Modena and Reggio Emilia in Italy presented data from 865 patients in MORE CARE...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiology

Viome’s CEO To Expand Into Clinical Diagnostics ‘For Which There Are No Solutions’ With AI, RNA Test

 
• By Marion Webb

Viome Life Sciences accelerates its push into clinical diagnostics with studies in colorectal cancer and a major partnership with Microsoft to scale its molecular data analysis platform. Viome leverages RNA analysis and AI to detect disease at the molecular level and personalize preventive health.

FDA Warning Letter To Philips Targets Three Facilities For Quality Control Failures

 
• By Brian Bossetta

US FDA inspections of three Philips manufacturing sites earlier this year resulted in a September warning letter that claimed the company was not in conformity with current good manufacturing practices. Philips says it is addressing the agency’s concerns and working to enhance its quality systems.

Could Oura Take A Bite Out Of Apple? Company Seeks FDA Clearance For Blood Pressure Feature

 
• By Brian Bossetta

Wearables innovator Oura has launched a profile study aimed at helping the company secure FDA clearance for a blood pressure feature for its smart ring. Study participants will answer questions while wearing the ring, which the company plans to use to support the feature’s efficacy.

Medicare’s TCET Pathway Wins Acclaim From Early Users, Even As ‘Messy Middle’ Persists

 
• By Brian Bossetta

Some of the first manufacturers to receive Medicare coverage for their breakthrough devices through the Transitional Coverage for Emerging Technologies pathway praise CMS’ engagement and timelines in the process, despite some challenges around post-launch data collection.

More from Device Area

Neuromodulation Tech Raises Billions Despite Commercial Uncertainty

 
• By Barnaby Pickering

The neuromodulation space is quickly filling with well-funded companies that have demonstrated early signs of success. However, with strategics seemingly unwilling to spend on novel technologies and pharma desperate to maintain its foothold in CNS, these companies will face many challenges.

LinusBio Extends Hair-Based Diagnostic Beyond Autism, Expands Into Japan

 
• By Marion Webb

After rolling out its hair-based autism diagnostic across the US, LinusBio is expanding into Japan and testing its “molecular movie” technology for ALS and other neurological disorders, aiming to deliver the first objective biomarkers in pediatric and neuropsychiatric care.

FDA Warning Letter To Philips Targets Three Facilities For Quality Control Failures

 
• By Brian Bossetta

US FDA inspections of three Philips manufacturing sites earlier this year resulted in a September warning letter that claimed the company was not in conformity with current good manufacturing practices. Philips says it is addressing the agency’s concerns and working to enhance its quality systems.